Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAXBiotechnology
+$0.00 today
- Market cap
- $622.71M
- Beta
- -0.53
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$2.59
Volume 1.30M
Average 0.54M
BCAX Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Bicara Therapeutics Inc. Common StockNASDAQ: BCAX
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 1810.0% from a year ago
Other current liabilities stood at $32.01M at the end of Q1 FY2026, up 1810.0% from a year earlier and up 43.4% from the prior quarter.
Context
- Other current liabilities amounted to 5.8% of total assets at the end of Q1 FY2026, up 5.4 pp from a year earlier.
- Other current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +1810.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 22.32M USD
- Year-over-year change
- +127.9%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.32M | +127.9% |
| FY2024 | 2024-12-31 | 9.79M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Other Current Liabilities vs competitors
How BCAX compares with its peers on the latest reported figures
- BCAX's Mar 2026 other current liabilities of $32.01M is the highest of the 6 companies compared; the peer median is $4.34M.
- Its year-over-year change of +1810.0% is the highest of 5, against a peer median of +58.5%.
- Other current liabilities amounts to 5.8% of total assets for BCAX, versus a peer median of 1.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
BCAXBicara Therapeutics Inc. Common Stock | Mar 2026 | $32.01M | +1810.0% | — | 5.8% |
| Mar 2026 | $18.45M | — | -8.5% | 8.5% | |
| Mar 2026 | $6.52M | +289.0% | +76.7% | 3.3% | |
| Mar 2026 | $4.34M | +55.4% | +77.6% | 1.1% | |
| Mar 2026 | $1.19M | -20.6% | +19.9% | 0.6% | |
| Mar 2026 | $509.4K | +61.7% | +18.6% | 0.9% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding BCAX) | $4.34M | +58.5% | +19.9% | 1.1% | |
Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Intrinsic Alpha fair value
Locked
Current Price
$9.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.